484PRetrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)

484PRetrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2018-10, Vol.29 (suppl_8)
Hauptverfasser: Sobrero, A, Lenz, H-J, Eng, C, Scheithauer, W, Middleton, G, Chen, W, Esser, R, Nippgen, J, Burris, H
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue suppl_8
container_start_page
container_title Annals of oncology
container_volume 29
creator Sobrero, A
Lenz, H-J
Eng, C
Scheithauer, W
Middleton, G
Chen, W
Esser, R
Nippgen, J
Burris, H
description
doi_str_mv 10.1093/annonc/mdy281.032
format Article
fullrecord <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdy281_032</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdy281.032</oup_id><sourcerecordid>10.1093/annonc/mdy281.032</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdy281_0323</originalsourceid><addsrcrecordid>eNqVkM1KAzEUhYMoOP48gLu7bMFpk5lpnXEnQ0V3ZXQfYnpLI5kkJHeqfRsf1ZG6cenqcOAc-PgYuxF8JnhTzpVz3ul5vzkUtZjxsjhhmVgsm7zmlThlGW-KMr9blNU5u0jpnXO-bIomY19VXa07pOhTQE1mj9A9vIByyh6SSeC3QDuE1fq5BYpG2XtokYZP06s3CHZIYKJxnlArB_s_zTgIigw6SjAJlKbwYWgHCbV3m9wah9AjqUTjSIP21seRQFkYzxojTPq2a6dX7GyrbMLr37xkt4-r1_Yp90OQIY4c8SAFlz8W5NGCPFqQo4Xyn_Nvzqxpdg</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>484PRetrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Sobrero, A ; Lenz, H-J ; Eng, C ; Scheithauer, W ; Middleton, G ; Chen, W ; Esser, R ; Nippgen, J ; Burris, H</creator><creatorcontrib>Sobrero, A ; Lenz, H-J ; Eng, C ; Scheithauer, W ; Middleton, G ; Chen, W ; Esser, R ; Nippgen, J ; Burris, H</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy281.032</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2018-10, Vol.29 (suppl_8)</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Sobrero, A</creatorcontrib><creatorcontrib>Lenz, H-J</creatorcontrib><creatorcontrib>Eng, C</creatorcontrib><creatorcontrib>Scheithauer, W</creatorcontrib><creatorcontrib>Middleton, G</creatorcontrib><creatorcontrib>Chen, W</creatorcontrib><creatorcontrib>Esser, R</creatorcontrib><creatorcontrib>Nippgen, J</creatorcontrib><creatorcontrib>Burris, H</creatorcontrib><title>484PRetrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVkM1KAzEUhYMoOP48gLu7bMFpk5lpnXEnQ0V3ZXQfYnpLI5kkJHeqfRsf1ZG6cenqcOAc-PgYuxF8JnhTzpVz3ul5vzkUtZjxsjhhmVgsm7zmlThlGW-KMr9blNU5u0jpnXO-bIomY19VXa07pOhTQE1mj9A9vIByyh6SSeC3QDuE1fq5BYpG2XtokYZP06s3CHZIYKJxnlArB_s_zTgIigw6SjAJlKbwYWgHCbV3m9wah9AjqUTjSIP21seRQFkYzxojTPq2a6dX7GyrbMLr37xkt4-r1_Yp90OQIY4c8SAFlz8W5NGCPFqQo4Xyn_Nvzqxpdg</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Sobrero, A</creator><creator>Lenz, H-J</creator><creator>Eng, C</creator><creator>Scheithauer, W</creator><creator>Middleton, G</creator><creator>Chen, W</creator><creator>Esser, R</creator><creator>Nippgen, J</creator><creator>Burris, H</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20181001</creationdate><title>484PRetrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)</title><author>Sobrero, A ; Lenz, H-J ; Eng, C ; Scheithauer, W ; Middleton, G ; Chen, W ; Esser, R ; Nippgen, J ; Burris, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdy281_0323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sobrero, A</creatorcontrib><creatorcontrib>Lenz, H-J</creatorcontrib><creatorcontrib>Eng, C</creatorcontrib><creatorcontrib>Scheithauer, W</creatorcontrib><creatorcontrib>Middleton, G</creatorcontrib><creatorcontrib>Chen, W</creatorcontrib><creatorcontrib>Esser, R</creatorcontrib><creatorcontrib>Nippgen, J</creatorcontrib><creatorcontrib>Burris, H</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sobrero, A</au><au>Lenz, H-J</au><au>Eng, C</au><au>Scheithauer, W</au><au>Middleton, G</au><au>Chen, W</au><au>Esser, R</au><au>Nippgen, J</au><au>Burris, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>484PRetrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)</atitle><jtitle>Annals of oncology</jtitle><date>2018-10-01</date><risdate>2018</risdate><volume>29</volume><issue>suppl_8</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Oxford University Press</pub><doi>10.1093/annonc/mdy281.032</doi></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2018-10, Vol.29 (suppl_8)
issn 0923-7534
1569-8041
language eng
recordid cdi_oup_primary_10_1093_annonc_mdy281_032
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title 484PRetrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T12%3A20%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=484PRetrospective%20RAS%20analysis%20of%20the%20EPIC%20trial:%20Cetuximab%20plus%20irinotecan%20vs%20irinotecan%20in%20patients%20(pts)%20with%20second-line%20metastatic%20colorectal%20cancer%20(mCRC)&rft.jtitle=Annals%20of%20oncology&rft.au=Sobrero,%20A&rft.date=2018-10-01&rft.volume=29&rft.issue=suppl_8&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy281.032&rft_dat=%3Coup%3E10.1093/annonc/mdy281.032%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdy281.032&rfr_iscdi=true